Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Accumulated Expenses (2019 - 2025)

Burning Rock Biotech has reported Accumulated Expenses over the past 7 years, most recently at $11.4 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 8.5% year-over-year to $11.4 million; the TTM value through Dec 2025 reached $11.4 million, down 8.5%, while the annual FY2025 figure was $11.6 million, 5.7% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $11.4 million at Burning Rock Biotech, up from $10.8 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $24.4 million in Q4 2022 and troughed at $9.2 million in Q1 2021.
  • A 5-year average of $14.5 million and a median of $13.0 million in 2024 define the central range for Accumulated Expenses.
  • Biggest five-year swings in Accumulated Expenses: soared 77.94% in 2022 and later tumbled 44.98% in 2024.
  • Year by year, Accumulated Expenses stood at $20.0 million in 2021, then grew by 22.19% to $24.4 million in 2022, then plummeted by 40.37% to $14.6 million in 2023, then decreased by 14.51% to $12.5 million in 2024, then dropped by 8.5% to $11.4 million in 2025.
  • Business Quant data shows Accumulated Expenses for BNR at $11.4 million in Q4 2025, $10.8 million in Q3 2025, and $10.5 million in Q2 2025.